Hyperpolarized Imaging for New Treatments

NCT04259970 | Active Not Recruiting Phase 4 DMC FDA Drug

• 1 other identifier: 2019-1051
• Study Type: interventional
• Target: 64
• Locations: 2 countries
• Sites: 4

Brief Summary

The introduction of triple combination CFTR modulator therapy for patients with Cystic Fibrosis (CF) with at least one copy of the deltaF508 mutation is expected to provide major health benefits, but will also require novel outcome measures that can detect CF lung disease at an early stage, capture the efficacy of new therapies when disease manifestations are limited, as well as determine whether stopping existing chronic maintenance therapies does not have negative effects. In the past decade, research has focused on the multiple breath washout (MBW) test, as a sensitive outcome measure, especially if highly-effective modulator therapies are initiated in early childhood. Even LCI, however, may not adequately capture early lung function changes, thus warranting investigation of even more sensitive outcome measures. Magnetic resonance imaging (MRI) has the advantage of being a radiation-free modality, making it more suitable for assessing response to therapy in a shorter time frame with repeated imaging. Inhalation of a hyperpolarized gas enables the visualization and quantification of regional ventilation in the lung and can be combined with structural MRI to assess both structure and function in parallel. The main Investigator and others have recently formed an international consortium (the 129Xe MRI Clinical Trial Consortium), comprised of both imaging experts and pulmonary clinicians to standardize imaging procedures, thus facilitating multi-site implementations. Data from this proposed study (HyPOINT; Hyperpolarized Imaging for New Treatments) will inform the future utility of MRI for both longitudinal studies to track disease progression over time as well as for future interventional trials. Further, the current study could inform the design of future trials of interventions of patients for whom currently no effective CFTR modulator therapy is available and for patients with rare genotypes thus laying the groundwork for a more personalized medicine approach in the near-term future.

Conditions

Cystic Fibrosis

Keywords

Cystic Fibrosis; CFTR modulator therapy; 129Xe MRI; hyperpolarized xenon; LCI

Outcome Measures

Primary Outcomes (2)

• Xe VDP Assessment

  The primary analysis will use a paired, non-parametric test (e.g., Wilcoxson Rank sum) to determine if the change in VDP from baseline to 28 days is statistically different from no change in VDP.

  28 days

• The change in Xe VDP after 28 days of triple modulator CFTR therapy

  To understand how triple combination therapy affects lung function in the long term, we will compare the changes in VDP (summarized as the average change from baseline at 6 months and 12 months), using the same non-parametric matched analysis. This will inform the natural history of VDP and whether future studies of hyperpolarized 129Xe MRI should be designed to show an improvement in VDP or maintenance of VDP. Exploratory analyses using a mixed-effects regression model will be done to define the rate of change of VDP over the 12-month study period.

  28 days

Secondary Outcomes (3)

• Overall UTE MRI reader score analysis

  28 days

• The change in overall MRI reader score for UTE MRI 28 days after triple combination therapy is initiated

  28 days

• Fev1 and LCI Correlation

  28 days

Study Arms (2)

Phase 1

EXPERIMENTAL

Phase 1 will include implementation of a centralized analysis program of repeated 129Xe MRI scanning in CF patients with mild lung disease to define the intra-subject variability of the primary outcome ventilation defect percentage (VDP). Patients will undergo baseline 129Xe MRI scanning and repeated measurements the same day, as well as at 28 days (± 7 days). Phase 1 will establish the intra-subject reproducibility to facilitate future use of 129Xe MRI in multi-site studies. Furthermore, the reproducibility limits defined will inform the overall design of future studies and will compare to established pulmonary function and multiple-breath washout testing (via measurement of the lung clearance index, LCI).

Drug: Initiation of CFTR Modulator

Initiation of CFTR Modulator

EXPERIMENTAL

Phase 2 will be an observational study of patients assessed before and after the clinical initiation of triple-combination modulator therapy (after presumed FDA and Health Canada approval). The primary endpoint for Phase 2 is the change of VDP after 28 days of triple-combination modulator therapy. Within Phase 2, this study will also address how highly-effective modulator therapies affect lung function trajectories by measuring 129Xe MRI at 28 days (± 7 days), 6 months (± 28 days), and 12 months (± 28 days) after start of therapy (paralleling time points of the PROMISE study). Finally, to understand how 129Xe MRI can be used in combination with existing measures of lung function (e.g. spirometry, multiple breath washout), the investigators will directly compare the repeated data collected in both Phase 1 and Phase 2 to these established measures of lung function that are currently used in observational and interventional studies.

Drug: Initiation of CFTR Modulator

Interventions

Initiation of CFTR Modulator DRUG

Inhaled contrast for MRI occurring at each 4 visits.

Also known as: 129Xe

Initiation of CFTR Modulator; Phase 1

Eligibility Criteria

• Age: 6 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Written informed consent (and assent when applicable) obtained from subject or subject's legal representative.
• Willingness and ability to adhere to the study visit schedule and other protocol requirements.
• Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
• Sweat chloride equal to or greater than 60 mEq/liter by quantitative pilocarpine iontophoresis test
• Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
• Phase 1 only: Age 6 to 18 years, inclusive, at the time of consent.
• Phase 2 only: Ages 9 to 18 years, inclusive, at the time of consent.
• Clinically stable with no acute antibiotic usage in the 14 days prior to the first visit.
• Genotype with F508del on at least one allele.
• No change in chronic pulmonary medications or therapies in the 28 days prior to the first visit.
• Stable CFTR modulator therapy (TEZ/IVA or LUM/IVA) for at least 28 days prior to the first visit or currently not receiving CFTR modulator therapy.
• Ability to cooperate with MRI procedures.
• Phase 1 only: FEV1 greater than or equal to 80% predicted based on GLI reference equations.

You may not qualify if:

• For females of childbearing potential: Positive urine pregnancy test at Screening or Visit 1 or Lactating.
• Any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Sponsors & Collaborators

• The Hospital for Sick Children: collaborator
• Children's Hospital Medical Center, Cincinnati: lead
• University of Virginia: collaborator
• University of Wisconsin, Madison: collaborator

Study Sites (4)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3019, United States

Location

University of Virginia School of Medicine

Charlottesville, Virginia, 22908, United States

Location

University of Wisconsin

Madison, Wisconsin, 53792, United States

Location

The Hospital for Sick Kids

Toronto, Ontario, M5G 1X8, Canada

Location

Related Publications (1)

• Wielputz MO, Puderbach M, Kopp-Schneider A, Stahl M, Fritzsching E, Sommerburg O, Ley S, Sumkauskaite M, Biederer J, Kauczor HU, Eichinger M, Mall MA. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med. 2014 Apr 15;189(8):956-65. doi: 10.1164/rccm.201309-1659OC.

  PMID: 24564281 BACKGROUND

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Study Officials

• Jason Woods, PhD

  Children's Hospital Medical Center, Cincinnati

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: DIAGNOSTIC
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2020
• First Posted: February 7, 2020
• Study Start: January 13, 2020
• Primary Completion: May 1, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: January 7, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1); US (3)